Biontech Se ADR (BNTX) Stock Price, Quote & News

Company Profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin a...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 6131 9084

Fax: 49 6131 9084

Website: www.biontech.de

Address:

An der Goldgrube 12, Mainz, Germany

taxplanr Apr. 8 at 4:47 PM

Theres is an actual nono material that kills Melanoma without harming healthy cells $BNTX $MRNA $MRK $BMY https://www.graphene-info.com/laser-induced-graphene-patch-delivers-noninvasive-low-temperature-melanoma

0 · Reply

taxplanr Apr. 8 at 2:09 PM

Chemo Avoided $BNTX $MRNA $MRK $PFE https://makisw.substack.com/p/ivermectin-fenbendazole-mcp-cbd-testimonial-58b?utm_source=post-email-title&publication_id=1385328&post_id=193542721&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

taxplanr Apr. 8 at 1:57 PM

Ivermectin + Mebendazole confirmed efficacy against 9 cancers $BNTX $MRNA $MRK $PFE https://makisw.substack.com/p/breaking-news-ivermectin-and-mebendazole?utm_source=post-email-title&publication_id=1385328&post_id=193493083&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

taxplanr Apr. 8 at 2:03 AM

What do you make of Project Artichoke? $BNTX $MRNA $PFE https://www.dailymail.co.uk/sciencetech/article-15585657/cia-project-artichoke-mind-control.html

0 · Reply

Ventureville Apr. 7 at 7:56 PM

Audit wraps April 28, trading stays open ($BIOV.CSE / $BVAXF). While $MRNA/$MRK and $BNTX grab headlines with mRNA cancer advances.

0 · Reply

Ventureville Apr. 7 at 7:53 PM

Chart noise aside. Tartaglia’s Sanofi vaccine experience fits perfectly with sector momentum ($MRNA/$MRK 49% RFS risk reduction at 5yrs, $BNTX platform plays). BioVaxys delivers MVP-S responses in ovarian (3yr CR) & bladder post-IO ($BIOV.CSE / $BVAXF), fresh Adiverna DPX-mRNA pet vaccines, Sona next steps - post-audit this could ride the immunotherapy rotation hard!

0 · Reply

DocPharm Apr. 7 at 3:17 PM

$ABUS $PFE $BNTX $ROIV limits set for dip Along with other non-bio/pharm names

0 · Reply

taxplanr Apr. 6 at 9:54 PM

mRNA injections the military $BNTX $MRNA $PFE https://www.instagram.com/reel/DWt031uiGHK/?igsh=MXEweWk2ZGoyb3hmOQ==

0 · Reply

Ventureville Apr. 6 at 7:58 PM

Are people sleeping on one of the most under the radar platform plays in biotech? $BIOV.CSE $BVAXF invited to present DPX to CEPI, the same group funding major mRNA pandemic programs alongside names like $MRNA $BNTX $PFE. At the same time, positive cancer Phase data and expansion into mRNA + infectious disease. Sector capital is flowing toward scalable platforms. 2026 could be the wake up year.

0 · Reply

taxplanr Apr. 6 at 6:00 PM

Latest C19 jabs study shows 100%of victims have clots $BNTX $MRNA $PFE https://www.instagram.com/reel/DWyzAKCDJDp/?igsh=MXMzNHptcmR1YXU4NA==

0 · Reply

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

PFE

Mar 24, 2026, 6:45 AM EDT - 15 days ago

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

Mar 10, 2026, 3:39 PM EDT - 4 weeks ago

BioNTech Stock Tanks As Outlook, Founder Exit Rattle Bulls

Mar 10, 2026, 2:48 PM EDT - 4 weeks ago

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 10, 2026, 1:29 PM EDT - 4 weeks ago

One simple reason why BioNTech stock is a raging buy on today's crash

Mar 10, 2026, 8:40 AM EDT - 4 weeks ago

BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture

Mar 10, 2026, 7:40 AM EDT - 4 weeks ago

Scientists behind COVID-19 vaccine will depart BioNTech

Mar 10, 2026, 7:18 AM EDT - 4 weeks ago

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.

Mar 10, 2026, 6:50 AM EDT - 4 weeks ago

BioNTech Cofounders to Leave to Form New Company

Mar 10, 2026, 6:49 AM EDT - 4 weeks ago

BioNTech's founding couple Sahin, Tuereci to leave to set up new venture

Mar 10, 2026, 6:45 AM EDT - 4 weeks ago

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Mar 10, 2026, 6:33 AM EDT - 4 weeks ago

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

Feb 24, 2026, 6:45 AM EST - 6 weeks ago

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

Feb 19, 2026, 1:25 PM EST - 6 weeks ago

BioNTech sues Moderna for patent infringement over COVID-19 shots

MRNA

Jan 28, 2026, 8:00 AM EST - 2 months ago

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

Jan 12, 2026, 6:45 AM EST - 3 months ago

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 10:00 AM EST - 3 months ago

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

Dec 18, 2025, 4:45 AM EST - 3 months ago

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

Dec 9, 2025, 7:00 AM EST - 4 months ago

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

BMY

Dec 6, 2025, 3:30 PM EST - 4 months ago

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Dec 3, 2025, 9:01 AM EST - 4 months ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

CVAC

Dec 1, 2025, 3:50 PM EST - 4 months ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

MRNA NVAX PFE

Dec 1, 2025, 12:35 PM EST - 4 months ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

MRNA NVAX PFE

Nov 26, 2025, 7:30 AM EST - 4 months ago

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Nov 13, 2025, 5:20 PM EST - 5 months ago

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

PFE

Nov 13, 2025, 11:10 AM EST - 5 months ago

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

PFE

Nov 13, 2025, 8:17 AM EST - 5 months ago

BioNTech says collaboration with Pfizer remains unchanged

PFE

Nov 3, 2025, 10:29 AM EST - 5 months ago

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

BMY

Nov 3, 2025, 6:47 AM EST - 5 months ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:45 AM EST - 5 months ago

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Oct 28, 2025, 7:45 AM EDT - 5 months ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 27, 2025, 7:45 AM EDT - 5 months ago

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

Oct 22, 2025, 6:45 AM EDT - 6 months ago

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Sep 23, 2025, 6:45 AM EDT - 7 months ago

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Sep 19, 2025, 11:40 AM EDT - 7 months ago

Mizuho's Jared Holz: There's not much value left in vaccine stocks

MRNA NVAX PFE

Sep 12, 2025, 1:37 PM EDT - 7 months ago

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

JNJ KVUE MRNA PFE

Sep 8, 2025, 2:01 PM EDT - 7 months ago

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BMY

Sep 8, 2025, 11:05 AM EDT - 7 months ago

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

BMY

Sep 8, 2025, 11:00 AM EDT - 7 months ago

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Sep 8, 2025, 7:02 AM EDT - 7 months ago

Pfizer, partner BioNTech say updated COVID shot shows better immune response

PFE

Sep 8, 2025, 6:45 AM EDT - 7 months ago

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

PFE

Sep 5, 2025, 5:13 AM EDT - 7 months ago

BioNTech, Duality score initial trial win with breast cancer precision drug

Aug 27, 2025, 12:50 PM EDT - 8 months ago

Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

PFE

Aug 7, 2025, 9:00 PM EDT - 8 months ago

CureVac settles patent dispute litigation with Pfizer and BioNTech

CVAC PFE

Aug 5, 2025, 1:36 PM EDT - 8 months ago

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

Aug 4, 2025, 10:32 AM EDT - 8 months ago

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

Aug 4, 2025, 7:01 AM EDT - 8 months ago

BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.

Aug 4, 2025, 6:52 AM EDT - 8 months ago

BioNTech's Q2 revenues double on higher COVID vaccine sales

Aug 4, 2025, 6:45 AM EDT - 8 months ago

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Aug 1, 2025, 4:51 PM EDT - 8 months ago

Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent

MRNA PFE

taxplanr Apr. 8 at 4:47 PM

0 · Reply

taxplanr Apr. 8 at 2:09 PM

0 · Reply

taxplanr Apr. 8 at 1:57 PM

0 · Reply

taxplanr Apr. 8 at 2:03 AM

What do you make of Project Artichoke? $BNTX $MRNA $PFE https://www.dailymail.co.uk/sciencetech/article-15585657/cia-project-artichoke-mind-control.html

0 · Reply

Ventureville Apr. 7 at 7:56 PM

Audit wraps April 28, trading stays open ($BIOV.CSE / $BVAXF). While $MRNA/$MRK and $BNTX grab headlines with mRNA cancer advances.

0 · Reply

Ventureville Apr. 7 at 7:53 PM

0 · Reply

DocPharm Apr. 7 at 3:17 PM

$ABUS $PFE $BNTX $ROIV limits set for dip Along with other non-bio/pharm names

0 · Reply

taxplanr Apr. 6 at 9:54 PM

mRNA injections the military $BNTX $MRNA $PFE https://www.instagram.com/reel/DWt031uiGHK/?igsh=MXEweWk2ZGoyb3hmOQ==

0 · Reply

Ventureville Apr. 6 at 7:58 PM

0 · Reply

taxplanr Apr. 6 at 6:00 PM

Latest C19 jabs study shows 100%of victims have clots $BNTX $MRNA $PFE https://www.instagram.com/reel/DWyzAKCDJDp/?igsh=MXMzNHptcmR1YXU4NA==

0 · Reply

Davidendz Apr. 6 at 4:43 PM

Pandemic preparedness is back in focus. CEPI continues backing scalable, platform based vaccine tech alongside names like $MRNA $BNTX and $PFE. Single dose, long duration delivery is a priority in global outbreak strategy. $BIOV.CSE $BVAXF aligning DPX with CEPI’s platform goals strengthens its infectious disease pipeline, including RSV and mRNA delivery. Platform relevance + global health alignment.

0 · Reply

MissionImpossibl Apr. 6 at 2:17 PM

$STX $WDC analysts upgrades are like $MRNA and $BNTX upgrades at peak : madness has no barriers

0 · Reply

I_Hate_Stock_Twits Apr. 3 at 6:42 PM

$BNTX This is why Robert Malone resigned. This recruitment stumble is a sham. No one will ever have to face the music. Still will never invest in this garbage. Shameful.

0 · Reply

Davidendz Apr. 3 at 1:37 PM

Biotech gets called “scam” on volatility, but that’s noise. What matters is data and execution. Across names like $BVAXF $BIOV.CSE,$MRNA, $BNTX, and $NVAX, it’s the same cycle: filings, catalysts, then price moves. Clinical progress > headlines.

0 · Reply

taxplanr Apr. 1 at 8:36 PM

What do you make of this testimony in front of the German Bundestag? $PFE $BNTX $MRNA https://www.instagram.com/reel/DWmYyx1jm4u/?igsh=MTBud3hycjBvM2J4ZA==

0 · Reply

AStrokeOfLuck Apr. 1 at 4:17 PM

$PFE $BNTX $MRNA $NVAX $SPY

2 · Reply

taxplanr Apr. 1 at 2:09 PM

Gastric tumors shrinking with Ivermectin and Fenbendazole $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-cc3?utm_source=post-email-title&publication_id=1385328&post_id=192824123&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

taxplanr Apr. 1 at 2:02 PM

Metastases shrinking with Ivermectin Fenbendazole and Mebendazole $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-mebendazole-fenbendazole-e15?utm_source=post-email-title&publication_id=1385328&post_id=192811753&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

Pillemann1 Apr. 1 at 8:45 AM

$BNTX https://www.ecdc.europa.eu/en/covid-19/variants-concern SARS-CoV-2 variants of concern as of 27 March 2026 Variant classification serves as an important communication tool for alerting EU/EEA countries about the emergence of SARS-CoV-2 variants with concerning properties likely to impact the epidemiological situation in the EU/EEA. The ECDC Strategic Analysis of Variants in Europe (SAVE) Working Group is a multidisciplinary team comprising of ECDC Experts working in Respiratory Viruses, Microbiology, Bioinformatics, Mathematical Modelling, Epidemic Intelligence, Emergency Preparedness and Response and Vaccine-Preventable Diseases and Immunisation. Currently meetings are held once per month to assess the observed or predicted impact of currently circulating and newly emerging SARS-CoV-2 variants in the EU/EEA and globally.

0 · Reply

PolycarpFX Mar. 31 at 10:34 PM

$BNTX

0 · Reply

taxplanr Mar. 31 at 4:31 PM

Bone tumors shrinking with Ivermectin Fenbendazole and Mebendazole $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-fenbendazole-and-mebendazole-454?utm_source=post-email-title&publication_id=1385328&post_id=192576453&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

1 · Reply

taxplanr Mar. 30 at 2:17 PM

Cancer Free in 1.5 months with Ivermectin and Fenbendazole $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-566?utm_campaign=email-half-post&r=18m8lm&utm_source=substack&utm_medium=email

0 · Reply

Market Cap	22.52B
Revenue (ttm)	3.25B
Net Income (ttm)	-1.29B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-39.59%
Debt to Equity Ratio	0.01

Volume	569,500
Avg Vol	1,132,310
Day's Range	N/A - N/A
Shares Out	251.33M
Stochastic %K	95%
Beta	1.58
Analysts	Strong Sell
Price Target	$136.68